OpenURL Connection Search

Select item for more details and to access through your institution.

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Published in:
Multiple Sclerosis Journal, 2020, v. 26, n. 13, p. 1729, doi. 10.1177/1352458519881761
By:
- Naismith, Robert T;
- Wolinsky, Jerry S;
- Wundes, Annette;
- LaGanke, Christopher;
- Arnold, Douglas L;
- Obradovic, Dragana;
- Freedman, Mark S;
- Gudesblatt, Mark;
- Ziemssen, Tjalf;
- Kandinov, Boris;
- Bidollari, Ilda;
- Lopez-Bresnahan, Maria;
- Nangia, Narinder;
- Rezendes, David;
- Yang, Lili;
- Chen, Hailu;
- Liu, Shifang;
- Hanna, Jerome;
- Miller, Catherine;
- Leigh-Pemberton, Richard
Publication type:
Article
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.
Published in:
British Journal of Clinical Pharmacology, 2022, v. 88, n. 6, p. 2909, doi. 10.1111/bcp.15229
By:
- Dijkstra, Francis M.;
- Zuiker, Rob G. J. A.;
- Siebenga, Pieter S.;
- Leigh‐Pemberton, Richard A.;
- Sun, Lei;
- Manthis, Joan D.;
- de Kam, Marieke L.;
- Lin, Richard;
- von Moltke, Lisa L.;
- Rezendes, David;
- van Gerven, Joop M. A.
Publication type:
Article
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Published in:
2020
By:
- Naismith, Robert T.;
- Wundes, Annette;
- Ziemssen, Tjalf;
- Jasinska, Elzbieta;
- Freedman, Mark S.;
- Lembo, Anthony J.;
- Selmaj, Krzysztof;
- Bidollari, Ilda;
- Chen, Hailu;
- Hanna, Jerome;
- Leigh-Pemberton, Richard;
- Lopez-Bresnahan, Maria;
- Lyons, Jennifer;
- Miller, Catherine;
- Rezendes, David;
- Wolinsky, Jerry S.;
- EVOLVE-MS-2 Study Group
Publication type:
journal article
Evaluation of Opioid Modulation in Major Depressive Disorder.
Published in:
Neuropsychopharmacology, 2015, v. 40, n. 6, p. 1448, doi. 10.1038/npp.2014.330
By:
- Ehrich, Elliot;
- Turncliff, Ryan;
- Du, Yangchun;
- Leigh-Pemberton, Richard;
- Fernandez, Emilio;
- Jones, Reese;
- Fava, Maurizio
Publication type:
Article
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
Published in:
2019
By:
- Palte, Michael J.;
- Wehr, Angela;
- Tawa, Mark;
- Perkin, Kristopher;
- Leigh-Pemberton, Richard;
- Hanna, Jerome;
- Miller, Catherine;
- Penner, Natasha
Publication type:
journal article

Found: 5

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

Evaluation of Opioid Modulation in Major Depressive Disorder.

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.